Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2004 3
2005 2
2006 3
2008 2
2009 4
2010 3
2011 7
2012 5
2013 7
2014 10
2015 10
2016 8
2017 5
2018 9
2019 7
2020 4
2021 1
2022 2
2023 2
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F. Olanow CW, et al. Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941. Epub 2017 Apr 3. Mov Disord. 2017. PMID: 28370340 Clinical Trial.
BACKGROUND: Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergistic mechanisms. ...METHODS: Previously untreated patients with early PD were randomized (1:1:1) to once-daily treatment with P2B001 (0.3 mg p …
BACKGROUND: Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergist …
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M. Barone P, et al. Eur J Neurol. 2015 Aug;22(8):1184-91. doi: 10.1111/ene.12724. Epub 2015 May 12. Eur J Neurol. 2015. PMID: 25962410 Free PMC article. Clinical Trial.
BACKGROUND AND PURPOSE: Depressed mood is a common psychiatric problem associated with Parkinson's disease (PD), and studies have suggested a benefit of rasagiline treatment. METHODS: ACCORDO (see the ) was a 12-week, double-blind, placebo-controlled trial to evaluate the …
BACKGROUND AND PURPOSE: Depressed mood is a common psychiatric problem associated with Parkinson's disease (PD), and studies have suggested …
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.
Reichmann H, Jost WH. Reichmann H, et al. Eur J Neurol. 2010 Sep;17(9):1164-1171. doi: 10.1111/j.1468-1331.2010.02986.x. Epub 2010 Mar 17. Eur J Neurol. 2010. PMID: 20236308 Clinical Trial.
RESULTS: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combination therapy) showed significant improvements from baseline in symptom severity (including classical motor and non-classical motor/non-motor …
RESULTS: Overall, 754 patients received rasagiline during the study. Patients treated with rasagiline (monotherapy or combinat …
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Wollebæk Johannesen S, Göricke B; RAS-ALS Study Group. Ludolph AC, et al. Lancet Neurol. 2018 Aug;17(8):681-688. doi: 10.1016/S1474-4422(18)30176-5. Epub 2018 Jun 19. Lancet Neurol. 2018. PMID: 29934198 Clinical Trial.
FINDINGS: Between July 2, 2013, and Nov 11, 2014, 273 patients were screened for eligibility, and 252 patients were randomly assigned to receive rasagiline (n=127) or placebo (n=125). 126 patients taking rasagiline and 125 taking placebo were included in the intenti …
FINDINGS: Between July 2, 2013, and Nov 11, 2014, 273 patients were screened for eligibility, and 252 patients were randomly assigned to rec …
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Zhang L, Zhang Z, Chen Y, Qin X, Zhou H, Zhang C, Sun H, Tang R, Zheng J, Yi L, Deng L, Li J. Zhang L, et al. Int J Neuropsychopharmacol. 2013 Aug;16(7):1529-37. doi: 10.1017/S1461145713000175. Epub 2013 Apr 3. Int J Neuropsychopharmacol. 2013. PMID: 23551956 Free article. Clinical Trial.
However, few studies have evaluated the efficacy and safety of rasagiline in the Chinese population. This study was designed to investigate the safety and efficacy of rasagiline as adjunctive therapy to levodopa treatment in Chinese PD patients. ...Scores using the …
However, few studies have evaluated the efficacy and safety of rasagiline in the Chinese population. This study was designed to inves …
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group. Parkinson Study Group. Arch Neurol. 2005 Feb;62(2):241-8. doi: 10.1001/archneur.62.2.241. Arch Neurol. 2005. PMID: 15710852 Clinical Trial.
Compared with placebo, patients treated with 1.0 mg/d rasagiline had 0.94 hour less off time per day, and patients treated with 0.5 mg/d rasagiline had 0.49 hour less off time per day. ...Rasagiline was well tolerated. CONCLUSIONS: Rasagiline improves …
Compared with placebo, patients treated with 1.0 mg/d rasagiline had 0.94 hour less off time per day, and patients treated with 0.5 m …
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. Rascol O, et al. Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Lancet Neurol. 2011. PMID: 21482191 Clinical Trial.
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. ...At week 36, both doses significantly improved UP …
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline …
Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial.
Li Y, Qi L, Bai H, Liu Y, Fan R, Tu Y, Sun Y, Wang J, Qi Q, Feng X, Zhou D, Wang X. Li Y, et al. Front Pharmacol. 2020 Dec 3;11:571747. doi: 10.3389/fphar.2020.571747. eCollection 2020. Front Pharmacol. 2020. PMID: 33364947 Free PMC article. Clinical Trial.
In each cycle of the study under both conditions, subjects received a single oral dose of 1 mg of a test or reference preparation of rasagiline tablets (1 mg each). A washout period of 3 days was observed. Blood samples were obtained up to 10 h post-intake. ...Results: The …
In each cycle of the study under both conditions, subjects received a single oral dose of 1 mg of a test or reference preparation of rasa …
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.
Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. Statland JM, et al. Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26. Muscle Nerve. 2019. PMID: 30192007 Free PMC article. Clinical Trial.
RESULTS: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerat …
RESULTS: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical contr …
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
Hattori N, Takeda A, Takeda S, Nishimura A, Kitagawa T, Mochizuki H, Nagai M, Takahashi R. Hattori N, et al. J Neural Transm (Vienna). 2019 Mar;126(3):299-308. doi: 10.1007/s00702-018-1964-3. Epub 2019 Jan 28. J Neural Transm (Vienna). 2019. PMID: 30689042 Free PMC article. Clinical Trial.
The incidence of treatment-emergent adverse events (TEAEs; primary outcome) was 53.7% and 77.8% in the placebo-rasagiline and rasagiline-rasagiline groups, respectively. Drug-related TEAEs occurred in 24.2% and 49.6% of patients and serious TEAEs occurred in …
The incidence of treatment-emergent adverse events (TEAEs; primary outcome) was 53.7% and 77.8% in the placebo-rasagiline and rasa …
83 results